D. E. Shaw & Co., Inc. Corvus Pharmaceuticals, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $156 Billion
- Q3 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 25,575 shares of CRVS stock, worth $224,292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,575Holding current value
$224,292% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
109Shares Held
38.3MCall Options Held
198KPut Options Held
167K-
Orbimed Advisors LLC San Diego, CA7.17MShares$62.8 Million1.75% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.45MShares$56.6 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$30.4 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$28.7 Million16.52% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$23.5 Million0.26% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $408M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...